New Search

Export article

De novo vasculitis after mRNA-1273 (Moderna) vaccination

, Michael Liu, Charalampos Saganas, Matteo Montani, Bruno Vogt, Uyen Huynh-Do, Daniel G. Fuster
Published: 31 May 2021

Abstract: The mRNA-1273 (Moderna) vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the current coronavirus disease 2019 (COVID-19) pandemic. In a randomized placebo-controlled phase 3 trial, the mRNA-1273 (Moderna) vaccine showed high efficacy at preventing COVID-19. Aside from transient local and systemic reactions, no safety concerns were identified.1Baden L.R. El Sahly H.M. Essink B. et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.N Engl J Med. 2021; 384: 403-416Crossref PubMed Scopus (490) Google Scholar
Keywords: vaccine / safety / Moderna / coronavirus / COVID / novo / identified.1Baden / encapsulated / stabilized / 416Crossref

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "Kidney International" .
References (6)
    Cited by 4 articles
      Back to Top Top